Peptide / Unit conversion

CJC-1295 (with DAC) reconstitution calculator

Enter your CJC-1295 (with DAC) vial size, the volume of liquid added and the dose to calculate concentration and syringe units.

Your inputs determine the result. This calculator does not recommend dosages.

Live readout

Set your draw.

Enter your vial strength, diluent, and dose to see the draw.

Mode
Resulting concentration -- mg/mL
Doses per vial --
Syringe

Conversion follows standard mg, mL, and U-100 syringe references.

Performs unit conversions only. Not medical advice. Consult your healthcare provider.

Save preset

After saving, open Presets at the top of the calculator to recall this setup.

Saved presets

No saved presets

Save a conversion from the calculator to recall it later.

    Units chart

    CJC-1295 (with DAC) units chart (mg to U-100 units)

    CJC-1295 (with DAC) units chart: mg to U-100 units

    CJC-1295 (with DAC) has a 2 mg example vial size (input) in PinPoint, separate from the no-DAC form. The app's description links the DAC modification to albumin binding and a longer half-life.

    Vial concentration

    Water mL is treated as final solution mL in these columns.

    CJC-1295 (with DAC): concentration in mg per mL
    Vial contents1 mL water2 mL water3 mL water
    2 mg2 mg/mL50 U-100 units per mg1 mg/mL100 U-100 units per mg0.6667 mg/mL150 U-100 units per mg

    Example vial size (input): 2 mg. No source is cited for this size; it is an arithmetic input, not a sourced fact.

    Amount to units

    Example amounts (arithmetic only, not doses).

    CJC-1295 (with DAC): amount to U-100 syringe units
    Amount (mg)2 mg + 1 mL2 mg + 2 mL2 mg + 3 mL
    0.04 mg2 units4 units6 units
    0.1 mg5 units10 units15 units
    0.2 mg10 units20 units30 units
    0.4 mg20 units40 units60 units
    1 mg50 units100 units150 unitsover one syringe

    Cited amounts

    No human dose has been established. The amount table contains arithmetic examples only.

    How to read this chart

    units = amount ÷ (vial mg ÷ water mL) × 100

    The reconstitution calculator walks through each step, and units to mg converts between mg, mcg, mL and units.

    An eight-day reference distinguishes this form

    The with-DAC entry stores a 192-hour half-life, equivalent to eight days, inside the 5.8 to 8.1 days estimated in the 2006 study of healthy adults. No half-life has been measured for the no-DAC form. Consequently, a log covering several days can remain within a single half-life of the with-DAC model. The suffix in the compound's name therefore identifies a substantive difference in the stored profile, not just a different spelling of the same chart.

    Route and identity alongside the name

    Subcutaneous is the route the 2006 human study used for CJC-1295 (with DAC). PinPoint's description calls it a modified GHRH analog rather than merging it with the no-DAC entry. The volume table uses the with-DAC example vial on every row, so its amount labels remain consistent with the profile identified above it.

    Small amounts from a 2 mg total

    The with-DAC example vial size (input) is 2 mg. Its five arithmetic portions are 0.04, 0.1, 0.2, 0.4, and 1 mg. In a 2 mL final volume, concentration is 1 mg per mL, making the numerical mg and mL values equal within that column. The 0.4 mg row, for example, becomes 0.4 mL and 40 U-100 units. That numerical equality is particular to the 1 mg per mL concentration; it disappears in the 1 mL and 3 mL columns.

    Another vial example

    How are CJC-1295 DAC and no-DAC vials measured and converted?

    PinPoint's example vial sizes (inputs) differ: 2 mg for the DAC form and 5 mg for the form without DAC. In a hypothetical 2 mL, that is 1 mg/mL and 2.5 mg/mL. Each U-100 unit then holds 10 mcg of the DAC form or 25 mcg of the form without DAC, so the same 10-unit mark is 100 mcg of one and 250 mcg of the other.

    The CJC-1295 with DAC units chart and no-DAC units chart repeat the volume arithmetic.

    with DAC: 2 mg ÷ 2 mL = 1 mg/mL; 1 unit = 10 mcg

    no DAC: 5 mg ÷ 2 mL = 2.5 mg/mL; 1 unit = 25 mcg

    Arithmetic example, not a dose.

    Compound profile

    CJC-1295 (with DAC) at a glance

    CJC-1295 with DAC is a long-acting analog of growth hormone-releasing hormone that binds to albumin in the blood.[1][2] A 2006 study in healthy adults estimated its half-life at 5.8 to 8.1 days.

    Regulatory status
    CJC-1295 with DAC is not approved as a medicine and is not part of any FDA-approved drug; in December 2024 FDA's review recommended against allowing it as a bulk substance for pharmacy compounding, and FDA lists CJC-1295 among substances that may present significant safety risks, noting serious adverse events including increased heart rate and systemic vasodilatory reaction.[3][4]
    Half-life
    An estimated 5.8 to 8.1 days in a 2006 study of healthy adults given CJC-1295 with DAC by subcutaneous injection.[1]
    Route
    Subcutaneous, the route used in the 2006 study of healthy adults.[1]
    Category
    Peptide
    Vial size
    2 mg, example vial size (input)

    Evidence

    What the research says

    The human CJC-1295 publication examined whether a long-acting GHRH analog could sustain growth hormone and IGF-I secretion. Two controlled studies enrolled healthy adults aged 21 to 61 years. Participants received subcutaneous injections, with single-administration and repeated-administration designs followed over 28 or 49 days.[1]

    Investigators measured peak hormone concentrations, hormone exposure over time, and standard pharmacokinetic parameters for CJC-1295. The estimated compound half-life ranged from 5.8 to 8.1 days. Growth hormone and IGF-I were separate measured outcomes, each with its own response duration following administration. In FDA's summary of the full paper, blood levels peaked 0.5 to 2 hours after injection, with a high degree of individual variability.[1][3]

    Repeated exposure produced evidence of a cumulative hormonal effect in that study population. PinPoint's arithmetic uses eight days as its timing reference, within the reported range. The paper concerns the long-acting CJC-1295 form; it cannot supply the missing human kinetics of a product described as CJC-1295 without DAC.[1][3]

    FDA's 2024 review notes that the developer withdrew CJC-1295 with DAC from clinical trials in 2006 after a participant in a phase 2 trial died; the attending physician attributed the death to coronary artery disease. The same review summarises adverse events in the healthy-adult trials: injection-site reactions in about 70% of participants, headache, diarrhea, systemic vasodilatory reactions (flushing, warmth, transient low blood pressure) in 30%, and a dose-dependent rise in heart rate.[3]

    What is the difference between CJC-1295 with DAC and no DAC?

    Both are analogues of the first 29 amino acids of growth-hormone-releasing hormone. DAC stands for drug affinity complex, a lysine with a reactive group added to the end of the peptide so that it binds to albumin in the blood [2][3]. An FDA evaluation document identifies the two forms, with and without that group, as distinct substances [3]. PinPoint keeps them as separate entries. Human studies exist only for the form with DAC [3].

    A 2005 rat study showed that GRF(1-29) conjugated to albumin through this chemistry still activated the growth-hormone-releasing receptor on the pituitary, and identified CJC-1295 as the lead compound [2]. The developers attributed the longer time in circulation to albumin binding; FDA notes that this has not been shown directly [2][3].

    No study reports a half-life for CJC-1295 without DAC, and FDA found no study of any kind showing the form without DAC is active [3].

    Timing

    Half-life and timing

    An estimated 5.8 to 8.1 days in a 2006 study of healthy adults given CJC-1295 with DAC by subcutaneous injection.[1]

    The stored 192 hours are equivalent to eight days. Two successive halvings span 16 days and leave 25%; five span 40 days and leave 3.125%. Those intervals are generated from a fixed reference without modeling absorption or additional administrations. The long axis reflects the library's with-DAC context. It is not evidence that a particular person has eliminated the compound by day 40, and it does not give the missing clinical information needed to choose an amount or interval.

    The cited half-life reference

    Clinical publication, 2006: estimated half-life 5.8 to 8.1 days after subcutaneous injection in healthy adults. The arithmetic below uses 192 hours (8 days); it is not a measurement of anyone's levels or of how long an effect lasts.[1]

    The with-DAC entry uses eight days as its representative scalar. The linked clinical publication reports an estimated half-life of 5.8 to 8.1 days, so the single input is a simplification of reported observations. For this long reference, even the four-half-life table stretches beyond a calendar month. A longer horizontal axis reflects the chosen input; it does not establish a longer clinical benefit.[1]

    Half-life varies with the person, formulation and study context. The linked publication reports an estimated half-life of 5.8 to 8.1 days.

    CJC-1295 (with DAC) decay table

    Starting at an arbitrary 100%, each elapsed half-life divides the remaining modeled amount by two: 100 × 2 raised to the power of minus elapsed hours divided by 192. It describes a single contribution with no additional entries, and the percentages are not percentages of benefit or activity. Five half-lives, 960 hours (40 days), leave 3.125%; decay never reaches zero, and this is not a detection window or washout instruction.

    Normalized amount remaining, using the 192-hour half-life
    Half-livesHoursDaysRemaining (rounded)
    000100.0%
    1192850.0%
    23841625.0%
    35762412.5%
    4768326.3%

    Calculator details

    About this calculation.

    What does CJC-1295 with DAC mean in a peptide guide?

    DAC stands for drug affinity complex, a lysine with a reactive group added to the end of the peptide so that it binds to albumin in the blood. FDA treats the forms with and without DAC as distinct active moieties.[2][3]

    Is the CJC-1295 with DAC example vial the same as the no-DAC example?

    PinPoint uses 2 mg as the with-DAC example vial size and 5 mg for the no-DAC example. Those are example inputs. A calculator needs the actual known total rather than assuming that similar compound names imply identical containers.

    Does albumin-binding context change the conversion formula?

    It informs the research description and timing model, not the dimensional equation. Concentration remains mass divided by volume. An extended half-life cannot be inserted into that division to obtain a different concentration or select an administration amount.

    What is the half-life of CJC-1295 with DAC?

    A 2006 study in healthy adults estimated 5.8 to 8.1 days. PinPoint's arithmetic uses 192 hours, which is eight days, as its model input.[1]

    What is the half-life of CJC-1295 no DAC?

    No study reports a half-life for CJC-1295 without DAC. FDA found no study of any kind showing the form without DAC is active.[3]

    Are CJC-1295 DAC and no DAC interchangeable in a log?

    No. FDA treats them as distinct active moieties, and PinPoint keeps them as separate entries with different example vial sizes. Logging one as the other would distort the totals.[3]

    What concentration is CJC-1295 (with DAC) at 2 mg in 1 mL?

    2 mg divided by 1 mL is 2 mg per mL. That volume spans 100 U-100 syringe units.

    How does 2 mL change the concentration of this CJC-1295 (with DAC) vial?

    2 mg divided by 2 mL is 1 mg per mL, half the concentration in the 1 mL column.

    What does the 3 mL column mean for CJC-1295 (with DAC)?

    2 mg divided by 3 mL is approximately 0.6667 mg per mL. The full 3 mL volume corresponds to 300 U-100 units.

    How many units is 0.2 mg of CJC-1295 (with DAC) from this vial in 2 mL?

    0.2 mg divided by 1 mg per mL is 0.2 mL, or 20 U-100 units.

    References

    Sources

    Sources checked against the cited documents on 19 November 2026.

    1. CJC-1295 (with DAC) in healthy adults, 2006 (PubMed 16352683)Abstract read 19 November 2026: two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, subcutaneous; "The estimated half-life of CJC-1295 was 5.8-8.1 d."Retrieved 2026-11-19 · human-study
    2. hGRF(1-29)-albumin bioconjugates in rats, 2005 (PubMed 15817669)Abstract: albumin bioconjugation of the with-DAC form in cultured rat pituitary cells and rats.Retrieved 2026-11-19 · animal-study
    3. FDA briefing document, Pharmacy Compounding Advisory Committee, 4 December 2024: CJC-1295-related bulk drug substancesRead in full 19 November 2026: status (PDF p. 7 to 8), time to peak and adverse events from the 2006 trials (p. 38, 41, 46), trial withdrawal (p. 23, 40), forms (p. 10, 36, 52).Retrieved 2026-11-19 · regulator
    4. FDA, certain bulk drug substances for use in compounding that may present significant safety risksContent current as of 22 April 2026; read on 19 November 2026.Retrieved 2026-11-19 · regulator
    5. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description

    Keep your protocol together

    Track the result in the app.

    Set up vials, log doses and sites, and see your next reminder in PinPoint for iOS.

    Download on the App Store
    Syringe readout: 10 units is 0.10 mL on a U-100 insulin syringe
    THE ARITHMETIC / 0.10 mL = 10 UNITS

    Keep exploring

    More tools

    PinPoint app icon

    Your next chapter starts here

    Start Day 1 with
    your numbers in place.

    Your doses, your schedule, your picture. Bring it together in PinPoint.

    Built for iPhone.

    Subscription through the App Store, cancel anytime in your Apple ID settings.